Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on MI-PAY GROUP PLC. We currently have 17 research reports from 3 professional analysts.
|30Jan17 07:00||RNS||Trading Update and Notice of Results|
|21Sep16 07:00||RNS||Interim Results|
|03Aug16 07:00||RNS||Trading Update|
|23Jun16 07:00||RNS||Directorate Change|
|17May16 14:50||RNS||Result of AGM|
|13Apr16 07:00||RNS||Preliminary Results|
|07Apr16 07:00||RNS||Notice of Results|
Frequency of research reports
Research reports on
MI-PAY GROUP PLC
MI-PAY GROUP PLC
30 Jan 17
Mi-Pay has released an encouraging trading statement this morning confirming FY16 revenue will be in line with ZC estimates at £3.3m (FY15: £3.0m). The yoy growth of 10% is ahead of the 5.7% reported in the interim results in late September 2016. The improvement in revenue has been driven by a c. 28% increase in transaction values processed that reached £83.0m, up from £65.0m in FY15. The net cash position of £3.5m is in line with the previous year and ahead of our £3.0m forecast. We view this positively as it provides increasing confidence that the business has the necessary cash resources to fund its self through to profitability. FY16 results, scheduled to be released on the 5th April, will provide more detail as to the underlying make-up of the performance. The group remains will positioned to deliver on its strategy and today’s statement provides confidence that our challenging growth assumption in FY17 can be met should growth in Asia come through strongly.
Encouraging HY16 results
21 Sep 16
Mi-Pay has released an encouraging set of interim results this morning, leaving the company well positioned to meet FY16 forecasts that were updated at the time of the trading statement (3rd August). Benefits from investment made in previous periods are now being demonstrated in the company’s performance with improved margin dynamics, reduced administrative expenses and a healthy cash position. The company is well financed having sufficient cash resources to fund itself until FY19 (assuming an unlikely scenario of there being no improvement from current rate of cash burn) and is well positioned to deliver on its strategy of delivering outsourced online payment solutions to the mobile operators.
H1 Trading update
03 Aug 16
Mi-Pay have released a trading update this morning showing good progress in improving efficiencies across the business. The group has seen improvements in gross margins and lower operating costs but somewhat disappointing revenue growth. Importantly the company continues to make good progress in moving towards generating positive monthly cash flow. The cash position was ahead of management expectations at £3.4m.
03 Aug 16
MEDAPHOR GROUP PLC (MED LN) | MI-PAY GROUP PLC (MPAY LN) | RED24 PLC (REDT LN) | SAREUM HLDGS PLC (SAR LN) | SCIENCE IN SPORT PLC (SIS LN) | STATPRO GROUP (SOG LN) | TECHFINANCIALS INC (TECH LN) | TECHFINANCIALS INC (TECH LN) | TELIT COMMUNICATIONS PLC (TCM LN) | VENN LIFE SCIENCES HLDGS PLC (VENN LN)
20 Feb 17
Hayward Tyler Group* (HAYT): Trading update and financial position (CORP) | Petra Diamonds (PDL): Interim results (BUY) | Gemfields* (GEM): Interim results (CORP) | Premaitha Health* (NIPT): Middle East momentum (CORP) | Sound Energy (SOU): Acquisition update and TE-8 well spud (HOLD) | Proactis* (PHD): Interim trading on track (CORP) | 7digital* (7DIG): Automotive contract win (CORP)
21 Feb 17
Lighthouse Group* (LGT): Middle Britain growth (CORP) | Utilitywise* (UTW): Double-digit sales growth (CORP) | Trakm8* (TRAK): Earnings expectations cut again (CORP) | dotDigital* (DOTC): Myriad growth opportunities (CORP) | Artilium* (ARTA): Five-year Telenet deal secured and prepaid (CORP) | Netcall* (NET): Cloud investment pays off (CORP)
N+1 Singer - Small-cap quantitative research - New quality style screen + 11 quality focus stocks
09 Feb 17
We introduce our fourth and final style screen representing “quality”. This screens for stocks with the best combination of high returns on capital/equity, EBIT margins and operating cash-flow conversion rates. These criteria should help us monitor how strong underlying returns translate into share price performance over time and under varying market conditions. The screen selects the “best” 25 stocks from our universe of just over 500 stocks and, as usual, we focus on a shorter list of stocks we cover or otherwise know and believe to be particularly interesting. We provide brief investment summaries on these focus stocks on pages 4 – 9. We will monitor performance and refresh the screen in approximately 3-4 months time.
The Slide Rule
12 Jan 17
What is The Slide Rule? The Slide Rule has been designed to dramatically simplify the identification of the best companies in the UK small/mid-cap sector by making a quantitative assessment of the relative potential of each company. At its core, The Slide Rule aims to identify those companies that create genuine shareholder value through strong returns on capital and solid growth, but also present a value opportunity with the potential tailwind of earnings momentum. Companies are assessed within a Quality, Value, Growth and Momentum (QVGM) framework.
Time to go over weight
24 Feb 17
We believe equity investors are taking an unnecessarily cautious stance on the construction sector. Forward looking indicators (e.g. consumer confidence, construction PMIs and housing starts) point to a stable market and recent sales LFL are particularly encouraging (e.g. Marshalls). Near term margins may suffer temporary distortions as inflationary pressures build. However, history has shown that modest input cost inflation is actually a positive for earnings growth in the sector. Therefore, as we move into 2018, margin trends are likely to surprise on the upside.
N+1 Singer - Morning Song 22-02-2017
22 Feb 17
CORETX (COR LN) Contract wins and new Lifestyle facility | Gooch & Housego (GHH LN) Solid Q1 trading plus earnings enhancing acquisition of StingRay Optics | NCC Group (NCC LN) Further issues in Assurance | PCI-PAL (PCIP LN) Strong H1 underpins positive outlook | UBM (UBM LN) Results | Verona Pharma (VRP LN) Phase IIa RPL554 add-on trial to tiotropium commenced